Your browser doesn't support javascript.
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
Koutsakos, Marios; Rowntree, Louise C; Hensen, Luca; Chua, Brendon Y; van de Sandt, Carolien E; Habel, Jennifer R; Zhang, Wuji; Jia, Xiaoxiao; Kedzierski, Lukasz; Ashhurst, Thomas M; Putri, Givanna H; Marsh-Wakefield, Felix; Read, Mark N; Edwards, Davis N; Clemens, E Bridie; Wong, Chinn Yi; Mordant, Francesca L; Juno, Jennifer A; Amanat, Fatima; Audsley, Jennifer; Holmes, Natasha E; Gordon, Claire L; Smibert, Olivia C; Trubiano, Jason A; Hughes, Carly M; Catton, Mike; Denholm, Justin T; Tong, Steven Y C; Doolan, Denise L; Kotsimbos, Tom C; Jackson, David C; Krammer, Florian; Godfrey, Dale I; Chung, Amy W; King, Nicholas J C; Lewin, Sharon R; Wheatley, Adam K; Kent, Stephen J; Subbarao, Kanta; McMahon, James; Thevarajan, Irani; Nguyen, Thi H O; Cheng, Allen C; Kedzierska, Katherine.
  • Koutsakos M; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Hensen L; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Chua BY; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • van de Sandt CE; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan.
  • Habel JR; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Zhang W; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Jia X; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Kedzierski L; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Ashhurst TM; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Putri GH; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Marsh-Wakefield F; Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, VIC, Australia.
  • Read MN; Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute and University of Sydney, Sydney, NSW, Australia.
  • Edwards DN; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia.
  • Clemens EB; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Wong CY; School of Computer Science, University of Sydney, Sydney, NSW, Australia.
  • Mordant FL; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Juno JA; School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Amanat F; Vascular Immunology Unit, Discipline of Pathology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
  • Audsley J; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
  • Holmes NE; School of Computer Science, University of Sydney, Sydney, NSW, Australia.
  • Gordon CL; The Westmead Initiative, University of Sydney, Sydney, NSW, Australia.
  • Smibert OC; School of Computer Science, University of Sydney, Sydney, NSW, Australia.
  • Trubiano JA; The Westmead Initiative, University of Sydney, Sydney, NSW, Australia.
  • Hughes CM; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Catton M; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Denholm JT; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Tong SYC; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Doolan DL; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kotsimbos TC; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
  • Jackson DC; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Krammer F; Department of Infectious Diseases, Austin Hospital, Heidelberg, VIC, Australia.
  • Godfrey DI; Department of Medicine and Radiology, University of Melbourne, Parkville, VIC, Australia.
  • Chung AW; Data Analytics Research and Evaluation (DARE) Centre, Austin Health and University of Melbourne, Heidelberg, VIC, Australia.
  • King NJC; Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia.
  • Lewin SR; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Wheatley AK; Department of Infectious Diseases, Austin Hospital, Heidelberg, VIC, Australia.
  • Kent SJ; Department of Infectious Diseases, Austin Hospital, Heidelberg, VIC, Australia.
  • Subbarao K; Department of Infectious Diseases, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
  • McMahon J; National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
  • Thevarajan I; Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia.
  • Nguyen THO; Department of Infectious Diseases, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
  • Cheng AC; National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
  • Kedzierska K; Department of Medicine (Austin Health), University of Melbourne, Heidelberg, VIC, Australia.
Cell Rep Med ; 2(3): 100208, 2021 03 16.
Article in English | MEDLINE | ID: covidwho-1065663
ABSTRACT
SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill defined. We analyzed 85 SARS-CoV-2-infected individuals at acute and/or convalescent time points, up to 102 days after symptom onset, quantifying 184 immunological parameters. Acute COVID-19 presented with high levels of IL-6, IL-18, and IL-10 and broad activation marked by the upregulation of CD38 on innate and adaptive lymphocytes and myeloid cells. Importantly, activated CXCR3+cTFH1 cells in acute COVID-19 significantly correlate with and predict antibody levels and their avidity at convalescence as well as acute neutralization activity. Strikingly, intensive care unit (ICU) patients with severe COVID-19 display higher levels of soluble IL-6, IL-6R, and IL-18, and hyperactivation of innate, adaptive, and myeloid compartments than patients with moderate disease. Our analyses provide a comprehensive map of longitudinal immunological responses in COVID-19 patients and integrate key cellular pathways of complex immune networks underpinning severe COVID-19, providing important insights into potential biomarkers and immunotherapies.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibody Formation Type of study: Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2021.100208

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibody Formation Type of study: Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2021.100208